Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.…
Realbotix Provides Update on Nasdaq Listing Timeline
Onconetix (NASDAQ: ONCO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 2.890 USD on 20 November 2026, down 99.8% over 52 weeks. Its 52-week range is 2.760 USD to 1610.00 USD: the price is 99.8% below the high and 4.7% above the low.
Its market capitalisation is 2.37M USD.
Onconetix reports return on equity of -89.0% and revenue down 66.1% year over year.
It holds more cash than debt, a net cash position of 2.64M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.